Melanoma of unknown origin with central nervous system metastases
Abstract
Melanoma is a tumor with high affinity for metastasis within the central nervous system (CNS). Brain metastases
indicate a poor prognosis for the patient, often causing deterioration of neurological functions, and thus the
patient’s quality of life. We present a case of a 72-year-old patient with diagnosed melanoma of unknown origin
in clinical stage IV with metastases to the brain, liver and lymph nodes with the current BRAF V600E mutation.
The patient underwent stereotactic radiotherapy to the area of changes within the central nervous system and
combined therapy involving encorafenib with binimetinib under the drug program of the National Health Fund
with a very good response. Despite the initial poor prognosis and the appearance of skin toxicities, the patient
is still undergoing oncological therapy, is in good general condition and has obtained a clear therapeutic benefit
from the use of anti-BRAF/MEK therapy.
Keywords: melanomaCNS metastasisfocus primarus ignotus
References
- Rutkowski P, Wysocki PJ, Kozak K, et al. l. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Prac. 2022; 18(6): 357–392.
- Homsi J, Kashani-Sabet M, Messina J, et al. Cutaneous Melanoma: Prognostic Factors. Cancer Control. 2017; 12(4): 223–229.
- Panagopoulos E, Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol. 1983; 23(1): 8–10.
- Mremi A, Goodluck G, Sadiq A, et al. Metastatic malignant melanoma of unknown primary site to the brain: A case report. Int J Surg Case Rep. 2021; 86: 106311.
- Gogas HJ, Flaherty KT, Dummer R, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Eur J Cancer. 2019; 119: 97–106.